Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
130.1 USD | +1.89% | -6.41% | -6.54% |
Mar. 12 | Illumina Investor Carl Icahn Withdraws Bid for Board Seat, Continues Legal Battle Over Grail Acquisition | MT |
Mar. 12 | Exclusive-Icahn drops Illumina board challenge threat, sources say | RE |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
- The company has a good ESG score relative to its sector, according to Refinitiv.
Strengths
- For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Over the past four months, analysts' average price target has been revised upwards significantly.
Weaknesses
- The company has insufficient levels of profitability.
- The company's enterprise value to sales, at 4.5 times its current sales, is high.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the past year, analysts have significantly revised downwards their profit estimates.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-6.54% | 20.3B | C+ | ||
+9.28% | 223B | B | ||
+8.70% | 184B | B- | ||
+16.38% | 140B | B- | ||
+16.31% | 97.17B | A- | ||
+5.51% | 67.87B | A- | ||
+21.77% | 55.51B | B+ | ||
+0.85% | 49.49B | B+ | ||
+5.08% | 43.22B | A | ||
+17.19% | 40.71B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock
- Equities
- Stock Illumina, Inc. - Nasdaq
- Ratings Illumina, Inc.